ERBB2 and breast cancer: Overexpression of AIB1 is present in 30–60% of human breast cancers and correlates with an aggressive tumor phenotype (HER2-overexpression, DNA-nondiploidy, high histological grade, and high Ki67/S-phase fraction) [1–3, 6–12].